New Drugs Build On Personalized Medicine Momentum In Lung Cancer
Executive Summary
Crop of new treatments with data at the European Society of Medical Oncology meeting includes second-generation inhibitors of ALK and heat shock protein 90.
You may also be interested in...
Ariad Unfazed By FDA Breakthrough Denial
FDA denied a “breakthrough” designation request for ALK/EGFR inhibitor AP26113, but the door is open for another try, and the undaunted company is launching a pivotal trial in NSCLC this quarter. Ariad also reported a continued successful launch of its leukemia drug Iclusig.
Ariad Unfazed By FDA Breakthrough Denial
FDA denied a “breakthrough” designation request for ALK/EGFR inhibitor AP26113, but the door is open for another try, and the undaunted company is launching a pivotal trial in NSCLC this quarter. Ariad also reported a continued successful launch of its leukemia drug Iclusig.
Ariad Unfazed By FDA Breakthrough Denial
FDA denied a “breakthrough” designation request for ALK/EGFR inhibitor AP26113, but the door is open for another try, and the undaunted company is launching a pivotal trial in NSCLC this quarter. Ariad also reported a continued successful launch of its leukemia drug Iclusig.